bleomycin + cisplatin + vindesine

This is a combination chemotherapy regimen consisting of three cytotoxic agents—bleomycin, cisplatin, and vindesine. Each drug has a distinct mechanism of action: - Bleomycin is an antitumor antibiotic that induces DNA strand breaks through free radical formation. - Cisplatin is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - Vindesine is a vinca alkaloid that disrupts microtubule assembly, thereby inhibiting mitosis. The combination has been studied primarily for the treatment of advanced non-small cell lung cancer (including squamous cell carcinoma, large-cell carcinoma, and adenocarcinoma) and epidermoid carcinoma of the esophagus. Clinical studies have shown partial remission rates above 50% in some patient populations. Toxicities are generally manageable but include nephrotoxicity (cisplatin), myelosuppression (vindesine), pulmonary toxicity (bleomycin), nausea/vomiting, and risk of severe complications such as renal failure or sepsis[1][3][4].

Other names

bleomycin + cisplatin + vindesine